BCIQ Profiles

Company Profile Report

Intranasal option

Why Canaan is backing Dauntless' intranasal somatostatin analog

Canaan Partners sees a clear market opportunity for a non-invasive somatostatin analog, prompting the VC to lead a $25 million series A extension for Dauntless Pharmaceuticals Inc.

The financing, announced Feb. 16, brings the round's final close to $32 million.

Read the full 397 word article

How to gain access

Continue reading with a
two-week free trial.